Efficacy and safety of lixisenatide once daily versus exenatide twice daily in type2diabetes inadequately controlled on metformin: A 24-week, randomized, open-label, active-controlled study (GetGoal-X)

Diabetes Care

Volumn 36, Issue 10, 2013, Pages 2945-2951

  Rosenstock, Julio ^a   Raccah, Denis ^b   Koranyi, Laszlo ^c   Maffei, Laura ^d   Boka, Gabor ^e   Miossec, Patrick ^e   Gerich, John E ^f  

^a DALLAS DIABETES AND ENDOCRINE CENTER AT MEDICAL CITY   (United States)

^b HÔPITAL SAINTE MARGUERITE   (France)

^c DRC Ltd   (Hungary)

^d Investigación Clinica Aplicada   (Argentina)

^e SANOFI   (France)

^f UNIVERSITY OF ROCHESTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EXENDIN 4; HEMOGLOBIN A1C; LIXISENATIDE; METFORMIN;

ADD ON THERAPY; ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIABETES CONTROL; DIARRHEA; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; PARALLEL DESIGN; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; REGRESSION ANALYSIS; RISK BENEFIT ANALYSIS; TREATMENT DURATION; VERY ELDERLY; VOMITING; WEIGHT REDUCTION; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; PEPTIDES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84883324640     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc12-2709     Document Type: Article

References (34)

1. Fineman MS, Cirincione BB, Maggs D, Diamant M. GLP-1 based therapies: differential effects on fasting and postprandial glucose. Diabetes Obes Metab 2012;14:675-688
2. Flint A, Raben A, Ersboll AK, Holst JJ, Astrup A. The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity. Int J Obes Relat Metab Disord 2001;25:781-792
3. Komatsu R, Matsuyama T, Namba M, et al. Glucagonostatic and insulinotropic action of glucagonlike peptide I-(7-36)- amide. Diabetes 1989;38:902-905
4. Nauck MA, Kleine N, Orskov C, Holst JJ, Willms B, Creutzfeldt W. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1993;36: 741-744
5. Willms B, Werner J, Holst JJ, Orskov C, Creutzfeldt W, Nauck MA. Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)- (7-36) amide in type 2 (noninsulin-dependent) diabetic patients. J Clin Endocrinol Metab 1996;81:327-332
6. Nathan DM, Buse JB, Davidson MB, et al.; American Diabetes Association; European Association for the Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009;32:193-203
7. Rodbard HW, Jellinger PS, Davidson JA, et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract 2009;15: 540-559
8. Nauck MA, Heimesaat MM, Behle K, et al. Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. J Clin Endocrinol Metab 2002; 87:1239-1246
9. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006; 368:1696-1705
10. Buse JB, Bergenstal RM, Glass LC, et al. Use of twice-daily exenatide in basal insulintreated patients with type 2 diabetes: a randomized, controlled trial. Ann Intern Med 2011;154:103-112
11. Buse JB, Rosenstock J, Sesti G, et al.; LEAD-6 Study Group. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallelgroup, multinational, open-label trial (LEAD-6). Lancet 2009;374:39-47
12. Christensen M, Knop FK. Once-weekly GLP-1 agonists: How do they differ from exenatide and liraglutide? Curr Diab Rep 2010;10:124-132
13. Werner U, Haschke G, Herling AW, Kramer W. Pharmacological profile of lixisenatide: A new GLP-1 receptor agonist for the treatment of type 2 diabetes. Regul Pept 2010;164:58-64
14. Ratner RE, Rosenstock J, Boka G; DRI6012 Study Investigators.Dose- dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebocontrolled trial. Diabet Med 2010;27:1024-1032
15. Fonseca VA, Alvarado-Ruiz R, Raccah D, Boka G, Miossec P, Gerich JE; EFC6018 GetGoal-Mono Study Investigators. Efficacy and safety of the once-daily GLP-1 receptor agonist lixisenatide in monotherapy: a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono). Diabetes Care 2012;35:1225-1231
16. Ahrén B, Leguizamo Dimas A, Miossec P, Saubadu S,Aronson R. Efficacy and safety of lixisenatide once-daily morning or evening injections in type 2 diabetes inadequately controlled on metformin (GetGoal-M). Diabetes Care 2013;36:2543-2550
17. Bolli G, Munteanu M, Dotsenko S, Niemoeller E, Boka G, Hanefield M. Efficacy and safety of lixisenatide once-daily versus placebo in patients with T2DM insufficiently controlled on metformin (GetGoal-F1). Poster presented at 47th AnnualMeeting of the European Association for the Study of Diabetes, 12-16 September 2011, Lisbon, Portugal. Diabetologia 2011; 54(Suppl. 1):1-542 [Abstract 78]
18. Pinget M, Goldenberg R, Niemoeller E, Muehlen-Bartmer I, Guo H, Aronson R. Efficacy and safety of lixisenatide once daily versus placebo in patients with type 2 diabetes insufficiently controlled on pioglitazone (GetGoal-P) Diabetes Obes Metab. 30 April 2013 [Epub ahead of print]
19. Riddle MC, Aronson R, Home P, et al. Adding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin: a 24-week, randomized, placebo-controlled comparison (GetGoal-L). Diabetes Care 2013;36:2489-2496
20. Riddle MC, Forst T, Aronson R, et al. Adding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine: a 24-week, randomized, placebo-controlled study (GetGoal- Duo 1) Diabetes Care 2013;36:2497-2503
21. Seino Y, Min KW, Niemoeller E, Takami A; EFC10887 GETGOAL-L Asia Study Investigators. Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal- L-Asia). Diabetes Obes Metab 2012;14: 910-917
22. European Medicines Agency. ICH Topic E9 Statistical Principles for Clinical Trials. Note for Guidance on Statistical Principles for Clinical Trials (CPMP/ICH/363/96) [Internet], 1998. Available from http://www .emea.europa.eu/docs/en-GB/document- library/Scientific-guideline/2009/09/ WC500002928.pdf. Accessed 12 December 2012
23. European Medicines Agency. ICH Topic E10 Choice of Control Group in Clinical Trials. Note for Guidance on Choice of Control Group in Clinical Trials (CPMP/ ICH/364/96) [Internet], 2001. Available from http://www.emea.europa.eu/ docs/en- GB/document-library/Scientific-guideline/ 2009/09/WC500002925.pdf. Accessed 12 December 2012
24. US Department of Health and Human Services Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). Guidance for Industry. E9 Statistical principles for Clinical Trials [Internet], 1998. Available from http:// www.fda.gov/downloads/ Drugs/Guidance ComplianceRegulatoryInformation/ Guidances/ucm073137.pdf. Accessed 12 December 2012
25. European Medicines Agency. Committee for proprietary medicinal products. Note for guidance on statistical principles for clinical trials. CPMP/ICH/363/96 [Internet], 1998. Available from http://www .emea.europa.eu/docs/en-GB/ document- library/Scientific-guideline/2009/09/ WC500002928.pdf. Accessed 12December 2012
26. Food and Drug Administration. Guidance for Industry. Diabetes mellitus: developing drugs and therapeutic biologics for treatment and prevention [Internet], 2008. Available from http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/ Guidances/ucm071624.pdf. Accessed 12 December 2012
27. DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformintreated patients with type 2 diabetes. Diabetes Care 2005;28:1092-1100
28. Nauck M, Frid A, Hermansen K, et al.; LEAD-2 Study Group. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care 2009;32:84-90
29. Pratley RE, Nauck M, Bailey T, et al.; 1860-LIRA-DPP-4 Study Group. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. Lancet 2010;375:1447-1456
30. European Medicines Agency. Guideline on clinical investigation of medicinal products in the treatment or prevention of diabetes mellitus. CPMP/EWP/1080/00 Rev. 1 [Internet], 2012. Available from http://www.ema.europa. eu/docs/en-GB/ document-library/Scientific-guideline/ 2012/06/WC500129256.pdf. Accessed 12 December 2012
31. Aroda VR, Ratner R. The safety and tolerability of GLP-1 receptor agonists in the treatment of type 2 diabetes: a review. Diabetes Metab Res Rev 2011;27:528-542
32. Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD; Exenatide-113 Clinical Study Group. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004; 27:2628-2635
33. Kendall DM, Riddle MC, Rosenstock J, et al. Effects of exenatide (exendin-4) on glycemic control over 30weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005;28:1083-1091
34. Zinman B, Gerich J, Buse JB, et al.; LEAD-4 Study Investigators. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care 2009;32:1224-1230